TXG

10x Genomics Inc. Class A Common Stock (TXG) | Rumor.io

10x Genomics

TXG

Attention (50-day avg)0.01%

Attention rank (50-day avg)#497

Bullish sentiment (50-day avg)90%

Price to earnings ratio-252.9

Market capitalization11.5B

Earnings per share-0.6

Dividend yield (TTM)—

Revenue (annual)642.8M

Net income (annual)-43.5M

Social

What share of all stock conversation is about TXG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.02	0.02% +0	0.01% +0	0% +0

Sep 22

$TXG, 10x Genomics, has surged 400% this year, with its chart resembling that of $SNDK in 2025.
The company's genomics megatrend has been paying off, with the stock hitting a new all-time high and being up 553% since the previous fall.
$TXG's price movement has been described as "crazy" with the stock up several hundred percent, and some investors are concerned about its current situation and potential price targets.

Generated by AI

Sentiment

Of the messages about TXG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	83.33% -16.67	99.81% +0.43	98.52% +15.52	75.72% -6.27
Bearish	16.67% +16.67	0.19% -0.43	1.48% -15.52	24.28% +6.27

Bullish· Feb 16

$TXG has shown a strong recovery from its worst performance in a year, with a bounce back in financials after a bad start to the year.
10x Genomics, Inc. has made a significant move higher on earnings, with a 13.32% increase in stock price and trading 31% above average volume.
Analysts are bullish on $TXG, with multiple firms raising their price targets, including Cowen & Co. to $57 and Canaccord Genuity to $58, driven by the company's positive quarterly earnings and outlook.

Bearish· Oct 10

10x Genomics, Inc. (TXG) has been shorted by an investor who rode the stock down from $70 to $14.1, anticipating another 50%+ drop.
The company's Q3 24 revenue fell short of expectations, with the CEO citing a more disruptive than anticipated transition to new commercial processes and organization.
The stock's pre-market trading plummeted 26% after missing Q3 sales targets, with sales falling 11% in the Americas and 40% of accounts seeing new ownership due to a company reorganization.

Generated by AI

Topics

Of the messages about TXG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	0%	90.46%	53.49%
Announcements	—	100%	9.16%	31.44%
Analysts	—	0%	0.38%	1.84%
Controversies	—	0%	0%	0.29%
Earnings	—	0%	0%	12.82%
Macro	—	0%	0%	0.12%

Oct 10

10x Genomics, Inc. ($TXG) reported Q3 24 revenue fell short of expectations, with a 1% YoY decrease, and a disruptive transition in commercial processes.
The company's CEO noted that the previously announced modifications to commercial processes and organization were more disruptive than anticipated, leading to challenges in the Americas market.
$TXG shares plummeted 26% in pre-market trading after missing Q3 sales targets, with sales falling 11% in the Americas due to the shake-up.

Generated by AI

Community

Of the messages about TXG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	44.74%	57.29%	49.1%
Newcomers	50%	55.26%	42.71%	50.9%

Regulars· Oct 10

10x Genomics' (TXG) shares plummeted 26% in premarket trading after the company reported a revenue decline of about 1% year over year to roughly $151.7 million for Q3.
Analysts polled by Capital IQ and FactSet expect Q3 revenue of $162.2 million, exceeding the company's guidance of $151.7 million, which led to a decline in share price.
The company cited an ongoing reorganization as the reason for the sales lag, which contributed to the decline in share price and missed expectations.

Newcomers· Feb 13

Investors are watching for a catalyst to trigger a turnaround, with some suggesting scalping may be a more viable strategy than holding through the current market conditions.
JP Morgan has raised its target price for TXG to $17 from $15.
The company's expansion in translational research and adoption of its FLEX APEX platform are seen as key drivers of growth in 2026.

Generated by AI

News

10x Genomics begins shipping Atera spatial biology platform

22h agoInvesting.com

10x Genomics launches Sentira cloud analysis platform

22h agoInvesting.com

10x Genomics (TXG) Stock Is Up, What You Need To Know

Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 2.8% in the afternoon session after Argus analyst John Eade initiated coverage on the company with a Buy rating.

1d agoYahoo Finance

10x Genomics (TXG) Stock Is Up, What You Need To Know

1d agoBarchart.com

10x Genomics Inc Shares Rise After Argus Research Initiates Coverage With Buy Rating

10x Genomics Inc (TXG) shares rose 3.1% in Monday trading after Argus Research initiated coverage of

1d agoYahoo Finance

Argus initiates 10X Genomics stock coverage with buy on Atera demand

1d agoInvesting.com

Also Discussed

Investors talking about TXG also mention

#	Name	Attention
1	Twist Bioscience CorporationTWST	0%-0.02
2	NSTG - NanoString Technologies, Inc.	——
3	Illumina Inc.ILMN	0%+0
4	Relay Therapeutics Inc.RLAY	0%new
5	Arcus Biosciences, Inc.RCUS	0%new
6	Nurix Therapeutics, Inc.NRIX	0%new
7	NVTA - Invitae Corporation	——
8	Kulicke & Soffa Industries, Inc.KLIC	0%0
9	Hornbeck Offshore Services, Inc.HLX	0%new
10	Cullinan Therapeutics Inc.CGEM	0%new

10x Genomics Inc. Class A Common Stock

Healthcare
Health Information Services

10x Genomics Inc. Class A Common Stock represents ownership in 10x Genomics, a life science technology company focused on products that help researchers study biology at high resolution. The company develops integrated instruments, consumables, and software used for single-cell and spatial biology workflows, supporting applications such as gene expression analysis, immune profiling, chromatin accessibility, spatial transcriptomics, and in situ exploration of tissue biology. Its main product families include the Chromium platform, the Chromium X series, Visium, and Xenium, which are used by academic researchers, pharmaceutical companies, biotechnology firms, and other scientific organizations. 10x Genomics serves global markets across the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. The stock is commonly associated with the broader life sciences tools and services sector, where the company plays a specialized role in enabling advanced biological research and data generation.

Website

Location

6230 Stoneridge Mall Road

Pleasanton, CA, 94588-3260

United States

Social

What share of all stock conversation is about TXG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.02	0.02% +0	0.01% +0	0% +0

Sep 22

$TXG, 10x Genomics, has surged 400% this year, with its chart resembling that of $SNDK in 2025.
The company's genomics megatrend has been paying off, with the stock hitting a new all-time high and being up 553% since the previous fall.
$TXG's price movement has been described as "crazy" with the stock up several hundred percent, and some investors are concerned about its current situation and potential price targets.

Generated by AI

Sentiment

Of the messages about TXG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	83.33% -16.67	99.81% +0.43	98.52% +15.52	75.72% -6.27
Bearish	16.67% +16.67	0.19% -0.43	1.48% -15.52	24.28% +6.27

Bullish· Feb 16

$TXG has shown a strong recovery from its worst performance in a year, with a bounce back in financials after a bad start to the year.
10x Genomics, Inc. has made a significant move higher on earnings, with a 13.32% increase in stock price and trading 31% above average volume.
Analysts are bullish on $TXG, with multiple firms raising their price targets, including Cowen & Co. to $57 and Canaccord Genuity to $58, driven by the company's positive quarterly earnings and outlook.

Bearish· Oct 10

10x Genomics, Inc. (TXG) has been shorted by an investor who rode the stock down from $70 to $14.1, anticipating another 50%+ drop.
The company's Q3 24 revenue fell short of expectations, with the CEO citing a more disruptive than anticipated transition to new commercial processes and organization.
The stock's pre-market trading plummeted 26% after missing Q3 sales targets, with sales falling 11% in the Americas and 40% of accounts seeing new ownership due to a company reorganization.

Generated by AI

Topics

Of the messages about TXG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	0%	90.46%	53.49%
Announcements	—	100%	9.16%	31.44%
Analysts	—	0%	0.38%	1.84%
Controversies	—	0%	0%	0.29%
Earnings	—	0%	0%	12.82%
Macro	—	0%	0%	0.12%

Oct 10

10x Genomics, Inc. ($TXG) reported Q3 24 revenue fell short of expectations, with a 1% YoY decrease, and a disruptive transition in commercial processes.
The company's CEO noted that the previously announced modifications to commercial processes and organization were more disruptive than anticipated, leading to challenges in the Americas market.
$TXG shares plummeted 26% in pre-market trading after missing Q3 sales targets, with sales falling 11% in the Americas due to the shake-up.

Generated by AI

Community

Of the messages about TXG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	44.74%	57.29%	49.1%
Newcomers	50%	55.26%	42.71%	50.9%

Regulars· Oct 10

10x Genomics' (TXG) shares plummeted 26% in premarket trading after the company reported a revenue decline of about 1% year over year to roughly $151.7 million for Q3.
Analysts polled by Capital IQ and FactSet expect Q3 revenue of $162.2 million, exceeding the company's guidance of $151.7 million, which led to a decline in share price.
The company cited an ongoing reorganization as the reason for the sales lag, which contributed to the decline in share price and missed expectations.

Newcomers· Feb 13

Investors are watching for a catalyst to trigger a turnaround, with some suggesting scalping may be a more viable strategy than holding through the current market conditions.
JP Morgan has raised its target price for TXG to $17 from $15.
The company's expansion in translational research and adoption of its FLEX APEX platform are seen as key drivers of growth in 2026.

Generated by AI

10x Genomics

Social

Sep 22

Bullish· Feb 16

Bearish· Oct 10

Oct 10

Regulars· Oct 10

Newcomers· Feb 13

10x Genomics begins shipping Atera spatial biology platform

10x Genomics launches Sentira cloud analysis platform

10x Genomics (TXG) Stock Is Up, What You Need To Know

10x Genomics (TXG) Stock Is Up, What You Need To Know

10x Genomics Inc Shares Rise After Argus Research Initiates Coverage With Buy Rating

Argus initiates 10X Genomics stock coverage with buy on Atera demand

Also Discussed

10x Genomics Inc. Class A Common Stock

Company Information

Location

10x Genomics begins shipping Atera spatial biology platform

10x Genomics launches Sentira cloud analysis platform

10x Genomics (TXG) Stock Is Up, What You Need To Know

10x Genomics (TXG) Stock Is Up, What You Need To Know

10x Genomics Inc Shares Rise After Argus Research Initiates Coverage With Buy Rating

Argus initiates 10X Genomics stock coverage with buy on Atera demand

Also Discussed

Social

Sep 22

Bullish· Feb 16

Bearish· Oct 10

Oct 10

Regulars· Oct 10

Newcomers· Feb 13